Author | William U. Shipley, MD

Articles

T1 High-Grade Bladder Cancer Recurring After BCGTherapy: A Curative Alternative to Radical Cystectomy Exists

September 15, 2013

Decades of experience now exist to support the use of chemoradiotherapy in the treatment of muscle-invasive bladder cancer. Chemoradiotherapy for T1 tumors that recur following bacillus Calmette-Guérin therapy is promising and provides an important curative alternative for those unable or unwilling to undergo radical cystectomy.

Commentary (Shipley): Organ Preservation in Muscle-Invasive Bladder Cancer

March 01, 2005

Drs. Fernando and Sandler havewritten a thorough review thathas documented why a bladder-conserving therapy can now bemore widely accepted treatment for patientswith muscle-invading bladdercancer. They have shown that this treatmentapproach, while selective, doeshave a high likelihood of eradicatingthe primary tumor, preserving good organfunction, and not compromisingpatient survival. These successful approacheshave evolved over the past 25years following initial reports of theeffectiveness of cisplatin against transitionalcell carcinoma and then reportsof added efficacy when cisplatinis given concurrently with radiation.

Commentary (Shipley): Current Management of Unusual Genitourinary Cancers

November 01, 1999

In this two-part article, Krieg and Hoffman review the management of patients with cancer of the penis and those with cancer of the urethra, respectively. Both of these cancers are uncommon, and, when they present as small, early, circumscribed lesions, both can be cured (with organ preservation) by radiation therapy. Also following organ preservation by radiation therapy, these patients must continue to be followed closely because 25% to 35% will develop a local recurrence and can be cured by prompt salvage surgery.

Combined Androgen Suppression/Radiotherapy Improves Progression-Free Survival

November 01, 1997

Over the past 10 years, the Radiation Therapy Oncology Group has evaluated, by Phase III trials, the value of using a combination regimen, including androgen suppression (goserelin [Zoladex] and flutamide [Eulexin]) and radiation therapy, in locally advanced prostate cancer. Androgen suppression prior to or during radiation has not been shown to increase overall survival, but it has been shown to increase progression-free survival and freedom from distant metastases. In addition, a subset of men with poorly differentiated tumors who received goserelin following external beam radiation have had a significant overall survival benefit at 5 years’ follow-up. [Oncol News Int 6(Suppl 3):19-20, 1997]